Table 1. Baseline characteristics.
The clinicopathologic features of patients with RET fusion-positive lung cancers treated with selpercatinib are summarized according to presence or absence of central nervous system (CNS) metastases at baseline. Statistical comparisons of the difference between these features in both populations (no CNS metastases and CNS metastases at baseline) are shown. Abbreviations: IQR – interquartile range.
| Clinicopathologic Features | All Cases (n=61) | No CNS metastases (n=31) | CNS Metastases (n=30) | P value |
|---|---|---|---|---|
| Age (median, IQR) | 65 (56, 71) | 64 (57, 71) | 65 (55–70) | 0.76 |
| Sex n, % | 0.13 | |||
| Male | 29 (48%) | 18 (58%) | 11 (37%) | |
| Female | 32 (52%) | 13 (42%) | 19 (63%) | |
| Smoking n, % | 0.24 | |||
| Former | 15 (25%) | 10 (32%) | 5 (17%) | |
| Never | 46 (75%) | 21 (68%) | 25 (83%) | |
| Histology n, % | 0.61 | |||
| Adenocarcinoma | 58 (95%) | 30 (97%) | 28 (90%) | |
| Other | 3 (5%) | 1 (3%) | 2 (6%) | |
| 5’ partner* n, % | ||||
| KIF5B present | 41 (67%) | 20 (65%) | 21 (70%) | 0.79 |
| Prior RET-directed tyrosine kinase inhibitor# n, % | 20 (33%) | 8 (26%) | 12 (40%) | 0.28 |
| Selpercatinib therapy line mean, (range) | 2 (1, 3) | 2 (1, 3) | 2 (2, 3) | 0.37 |
| CNS treatment | ||||
| Prior CNS RT | 12 (20%) | 0 (0%) | 12 (40%) | <0.001 |
| Prior CNS surgery | 3 (5%) | 0 (0%) | 3 (10%) | 0.11 |
*
Some patients had >1 fusion.
#
some patients had more than one prior line of TKI therapy.